Barbara Schrörs

Dr. Barbara Schrörs

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
FLFranziska Lang
Franziska Lang
BSBarbara Schrörs
Barbara Schrörs
MLMartin Löwer
Martin Löwer
ÖTÖzlem Türeci
Özlem Türeci
USUgur Sahin
Ugur Sahin

4 April 2022 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
DWDavid Weber
David Weber
JIJonas Ibn-Salem
Jonas Ibn-Salem
PSPatrick Sorn
Patrick Sorn
MSMartin Suchan
Martin Suchan
CHChristoph Holtsträter
Christoph Holtsträter
USUgur Sahin
Ugur Sahin

15 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LKLeonard Kaps
Leonard Kaps
AHAnne Huppertsberg
Anne Huppertsberg
NCNiklas Choteschovsky
Niklas Choteschovsky
AKAdrian Klefenz
Adrian Klefenz
FDFeyza Durak
Feyza Durak
LNLutz Nuhn
Lutz Nuhn
Significance: Fibrosis is a consequence of most chronic liver diseases, but currently no approved antifibrotic treatment is available. M2-type macrophages drive fibrosis progression and prevent regression, even when effective causal therapies have been employed. M2-type macrophages activate a cascade of fibrogenic effector cells and can prevent removal of excess scar tissue. To switch these profibrogenic M2 to fibrolytic (regenerative) macrophages, we developed a pH-degradable, nanogel-based delivery system which can be covalently functionalized with the macrophage-repolarizing bisphosphonate alendronate. The nanogels efficiently deliver the clinically approved drug into hepatic nonparenchymal cells after intravenous administration. They do not eliminate macrophages but repolarize their phenotype and subsequently block fibrosis progression. This approach establishes a nanotherapeutic delivery platform to treat further M2-type macrophage-driven diseases, including cancer.

10 May 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
FLFranziska Lang
Franziska Lang
PRPablo Riesgo-Ferreiro
Pablo Riesgo-Ferreiro
MLMartin Löwer
Martin Löwer
USUgur Sahin
Ugur Sahin
BSBarbara Schrörs
Barbara Schrörs
The detection and prediction of true neoantigens is of great importance for the field of cancer immunotherapy. Wesearched the literature for proposed neoantigen features and integrated them into a toolbox called NEOantigen Feature toolbOX (NeoFox). NeoFox is an easy-to-use Python package that enables the annotation of neoantigen candidates with 16 neoantigen features. NeoFox is freely available as an open source Python package released under the GNU General Public License (GPL) v3 license at https://github.com/TRON-Bioinformatics/neofox. Supplementary data are available at Bioinformatics online.

1 January 2024 in Bioinformatics Advances
Verified
Journal Article
Open access
PDF file
FLFranziska Lang
Franziska Lang
PSPatrick Sorn
Patrick Sorn
MSMartin Suchan
Martin Suchan
AHAlina Henrich
Alina Henrich
CAChristian Albrecht
Christian Albrecht
JIJonas Ibn-Salem
Jonas Ibn-Salem
Neoantigens are promising targets for cancer immunotherapies and might arise from alternative splicing. However, detecting tumor-specific splicing is challenging because many non-canonical splice junctions identified in tumors also appear in healthy tissues. To increase tumor-specificity, we focused on splicing caused by somatic mutations as a source for neoantigen candidates in individual patients. We developed the tool splice2neo with multiple functionalities to integrate predicted splice effects from somatic mutations with splice junctions detected in tumor RNA-seq and to annotate the resulting transcript and peptide sequences. Additionally, we provide the tool EasyQuant for targeted RNA-seq read mapping to candidate splice junctions. Using a stringent detection rule, we predicted 1.7 splice junctions per patient as splice targets with a false discovery rate below 5% in a melanoma cohort. We confirmed tumor-specificity using independent, healthy tissue samples. Furthermore, using tumor-derived RNA, we confirmed individual exon-skipping events experimentally. Most target splice junctions encoded neoepitope candidates with predicted MHC-I or MHC-II binding. Compared to neoepitope candidates from non-synonymous point mutations, the splicing-derived MHC-I neoepitope candidates had lower self-similarity to corresponding wild-type peptides. In conclusion, we demonstrate that identifying mutation-derived, tumor-specific splice junctions can lead to additional neoantigen candidates to expand the target repertoire for cancer immunotherapies. The R package splice2neo and the python package EasyQuant are available at https://github.com/TRON-Bioinformatics/splice2neo and https://github.com/TRON-Bioinformatics/easyquant, respectively. Supplementary data are available at Bioinformatics Advances online.

13 October 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JWJian Wang
Jian Wang
TWTobias Weiss
Tobias Weiss
MNMarian C. Neidert
Marian C. Neidert
NTNora C. Toussaint
Nora C. Toussaint
RNReza Naghavian
Reza Naghavian
RMRoland Martin
Roland Martin
Purpose: The low mutational load of some cancers is considered one reason for the difficulty to develop effective tumor vaccines. To overcome this problem, we developed a strategy to design neopeptides through single amino acid mutations to enhance their immunogenicity. Experimental Design: Exome and RNA sequencing as well as in silico HLA-binding predictions to autologous HLA molecules were used to identify candidate neopeptides. Subsequently, in silico HLA-anchor placements were used to deduce putative T-cell receptor (TCR) contacts of peptides. Single amino acids of TCR contacting residues were then mutated by amino acid replacements. Overall, 175 peptides were synthesized and sets of 25 each containing both peptides designed to bind to HLA class I and II molecules applied in the vaccination. Upon development of a tumor recurrence, the tumor-infiltrating lymphocytes (TIL) were characterized in detail both at the bulk and clonal level. Results: The immune response of peripheral blood T cells to vaccine peptides, including natural peptides and designed neopeptides, gradually increased with repetitive vaccination, but remained low. In contrast, at the time of tumor recurrence, CD8+ TILs and CD4+ TILs responded to 45% and 100%, respectively, of the vaccine peptides. Furthermore, TIL-derived CD4+ T-cell clones showed strong responses and tumor cell lysis not only against the designed neopeptide but also against the unmutated natural peptides of the tumor. Conclusions: Turning tumor self-peptides into foreign antigens by introduction of designed mutations is a promising strategy to induce strong intratumoral CD4+ T-cell responses in a cold tumor like glioblastoma.